Open AccessepiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer
Author(s) -
Eve O’Reilly,
Alexandra V. Tuzova,
Anna Walsh,
Niamh Russell,
Odharnaith O’Brien,
Sarah Kelly,
Odhari Dhomhnallain,
Liam DeBarra,
Connie M Dale,
Rick Brugman,
Gavin Clarke,
Olivia Schmidt,
Shane Ó’Meachair,
Dattatraya Patil,
Kathryn L. Pellegrini,
Neil Fleshner,
Julia Garcia,
Fang Zhao,
Stephen Finn,
Robert Mills,
Marcelino Yazbek Hanna,
Rachel Hurst,
Elizabeth McEvoy,
William M. Gallagher,
Rustom P. Manecksha,
Christopher S. Cooper,
Daniel Brewer,
Bharati Bapat,
Martin G. Sanda,
Jeremy Clark,
Antoinette S. Perry
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00134
Subject(s) - prostate cancer , dna methylation , receiver operating characteristic , urine , biopsy , prostate biopsy , medicine , prostate , pca3 , oncology , cancer , liquid biopsy , epigenetics , methylation , prospective cohort study , urology , biology , gene , genetics , gene expression
Liquid biopsies that noninvasively detect molecular correlates of aggressive prostate cancer (PCa) could be used to triage patients, reducing the burdens of unnecessary invasive prostate biopsy and enabling early detection of high-risk disease. DNA hypermethylation is among the earliest and most frequent aberrations in PCa. We investigated the accuracy of a six-gene DNA methylation panel (Epigenetic Cancer of the Prostate Test in Urine [epiCaPture]) at detecting PCa, high-grade (Gleason score greater than or equal to 8) and high-risk (D'Amico and Cancer of the Prostate Risk Assessment] PCa from urine.